Data +Jul 14, 2026
Positive data — Biogen Shares Rise After Positive Phase 2 Alzheimer’s Trial Results (BIIB)▸
high impact
ApprovalJul 14, 2026
FDA approval — Biogen Wins FDA Approval for Subcutaneous Starter Dose of Leqembi▸
high impact
Data −Jul 14, 2026
Negative data — BIIB Stock On Track For Worst Day In 2 Years After RBC Questions If Alzheimer’s Drug Benefits Will Replicate In Further…▸
high impact
FilingJul 13, 2026
Regulatory filing — Eisai Co And Biogen Receive FDA's Approval For A Supplemental Biologics License Application For A Once-Weekly Lecanemab…▸
medium impact
ApprovalJul 13, 2026
FDA approval — FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease▸
high impact
DealJul 05, 2026
Deal — Here is Why Biogen (BIIB) is One of the Most Undervalued NASDAQ Stocks to Buy Right Now▸
medium impact
EarningsJul 01, 2026
Q1 2026 report-1.9%muted
DealJun 18, 2026
Deal — Biogen to Strengthen Immunology Pipeline With $1B RayThera Buyout▸
medium impact
DealJun 17, 2026
Deal — Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.▸
medium impact
ReadoutJun 11, 2026
Clinical data — What Makes Denali Therapeutics (DNLI) One of the Best AI Driven Biotech Names▸
medium impact
Data +Jun 05, 2026
Positive data — Should Biogen’s (BIIB) New SMA Breakthrough and Lupus Data Prompt a Fresh Look From Investors?▸
high impact
Data −Jun 02, 2026
Negative data — Biogen Ends BIIB122 Parkinsons Trial And Refocuses Neurodegeneration Pipeline▸
high impact
Data −May 22, 2026
Negative data — Biogen Faces Trial Setbacks And Probes That Reframe Neuro Pipeline Risks▸
high impact
Data −May 21, 2026
Negative data — Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Dis…▸
high impact
ReadoutMay 18, 2026
Clinical data — Biogen’s Apellis Deal And Alzheimer’s Trial Shift Focus Beyond Price▸
medium impact
Data −May 14, 2026
Negative data — Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Co…▸
high impact
Data +May 14, 2026
Positive data — Biogen stock jumps 10% on positive phase 2 diranersen data for Alzheimer’s▸
high impact
DealMay 14, 2026
Deal — Biogen Completes Acquisition of Apellis Pharmaceuticals▸
medium impact
AdComMay 08, 2026
FDA advisory — Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early A…▸
high impact
EarningsApr 29, 2026
Q1 2026 report-3.7%negative
DealApr 29, 2026
Deal — Biogen Q1 Earnings Call Highlights▸
medium impact
EarningsApr 06, 2026
Q1 2026 report+2.8%muted
EarningsFeb 06, 2026
FY 2025 report-5.0%negative
EarningsJan 13, 2026
FY 2025 report-7.8%negative
EarningsOct 30, 2025
Q3 2025 report-0.2%muted
EarningsOct 14, 2025
Q3 2025 report-1.6%muted
EarningsJul 31, 2025
Q2 2025 report+3.8%positive
EarningsJul 07, 2025
Q2 2025 report+4.0%positive
EarningsMay 01, 2025
Q1 2025 report-3.4%negative
EarningsFeb 12, 2025
FY 2024 report+2.4%muted
EarningsOct 30, 2024
Q3 2024 report-4.2%negative
EarningsAug 01, 2024
Q2 2024 report-5.0%negative